SynthesisMovement disorders : official journal of the Movement Disorder Society2022
The Movement Disorder Society Criteria for the Diagnosis of Multiple System Atrophy.
Synthesis in Movement disorders : official journal of the Movement Disorder Society, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 3 registered trials, which are not on this map. Cited by 484 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Integrated Management of Atypical Parkinsonism: A Home-based Patient-Centered Healthcare Delivery Based on Telenursing. A Multicenter, Interventional Non-pharmacological, Randomized, Single-blind Clinical Trial. IMPACT Study
Medical Decision Making in Multiple System Atrophy: Developing Personalized Best Medical Care with Integrated Telemedicine and Mobile Palliative Care for Individuals with Multiple System Atrophy
A Phase 2a Study to Evaluate Microglial Activation, Safety, and Clinical Effects of Foralumab Nasal in Patients With Multiple System Atrophy (MSA)
Who cites it
484 citing papers in PubMed, 3 syntheses or guidelines pooled it, 721 citations in OpenAlex.
- Tremor in multiple system atrophy: a systematic literature review.Journal of neural transmission (Vienna, Austria : 1996) · 2026Pooled it
- Vestibular Dysfunction in Parkinson's Disease: A Systematic Review of Signs and Symptoms.Movement disorders clinical practice · 2026Pooled it
- The Utility of Olfactory Testing to Discriminate Parkinson's Disease From Diagnostic Mimics: A Systematic Review and Meta-Analysis.European journal of neurology · 2026Pooled it
- Speech Treatment for People with Cerebellar Multiple System Atrophy (MSA-C): A Pilot Randomised Controlled Trial of Two Approaches.Cerebellum (London, England) · 2025Trial
- Multimodal neuroimaging in dementia and neurodegenerative disorders: complementary roles of clinically available nuclear medicine and MRI in the era of disease-modifying therapies.Japanese journal of radiology · 2026Review
- Neural Correlates of Apathy in Multiple System Atrophy: A Clinical and Perfusion Imaging Study.European journal of neurology · 2026Article
- Semiquantitative [¹²³I]FP-CIT SPECT metrics combined with machine learning improve clinical differentiation of Parkinson's disease and atypical parkinsonian syndrome.European journal of nuclear medicine and molecular imaging · 2026Article
- Large-scale genetic profiling of hereditary ataxias in China: implications for a stepwise molecular diagnostic strategy.Translational neurodegeneration · 2026Article
- Distinct EEG functional network alterations in Parkinson's disease and multiple system atrophy.NeuroImage. Clinical · 2026Article
- Sleep-Autonomic Interactions in Parkinson's Disease and Multiple System Atrophy: A Comparative Study Using Structural Equation Modeling.Movement disorders clinical practice · 2026Article
- Plasma neurofilament light for early differentiation of multiple system atrophy from Parkinson disease.EBioMedicine · 2026Article
- Lower Urinary Tract Symptoms as Diagnostic Clues in Parkinsonism: A Practical Framework for Neurologists.Movement disorders clinical practice · 2026Review
- Dopaminergic Radiopharmaceutical Imaging in Parkinsonian Syndromes: From Molecular Targets to Clinical Decision-Making.Pharmaceuticals (Basel, Switzerland) · 2026Review
- Regional reduction of high-energy phosphorus metabolites characterizes the cerebellar subtype of multiple system atrophy.NPJ Parkinson's disease · 2026Article
- α-Synuclein strain homogeneity in multiple system atrophy subtypes.Brain pathology (Zurich, Switzerland) · 2026Article
- Cutaneous alpha-synuclein deposition informs autonomic function in individuals with early-stage multiple system atrophy.Clinical autonomic research : official journal of the Clinical Autonomic Research Society · 2026Article
- Long-Term Income and Productivity Losses in Individuals With Early-Onset Dementia: Evidence From 15 Years Preceding the Diagnosis.Neurology · 2026Article
- Patterns of iron deposition and classification in parkinsonian syndromes: a quantitative susceptibility mapping study.Journal of neurology · 2026Article
- Feasibility of short imaging protocols for [European journal of nuclear medicine and molecular imaging · 2026Article
- Cerebral metabolic trajectories alterations in multiple system atrophy: A longitudinal FDG-PET study.Journal of Parkinson's disease · 2026Article
424 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
29 authors at 19 institutions in 14 countries.
Funding
Abstract
backgroundThe second consensus criteria for the diagnosis of multiple system atrophy (MSA) are widely recognized as the reference standard for clinical research, but lack sensitivity to diagnose the disease at early stages.
objectiveTo develop novel Movement Disorder Society (MDS) criteria for MSA diagnosis using an evidence-based and consensus-based methodology.
methodsWe identified shortcomings of the second consensus criteria for MSA diagnosis and conducted a systematic literature review to answer predefined questions on clinical presentation and diagnostic tools relevant for MSA diagnosis. The criteria were developed and later optimized using two Delphi rounds within the MSA Criteria Revision Task Force, a survey for MDS membership, and a virtual Consensus Conference.
resultsThe criteria for neuropathologically established MSA remain unchanged. For a clinical MSA diagnosis a new category of clinically established MSA is introduced, aiming for maximum specificity with acceptable sensitivity. A category of clinically probable MSA is defined to enhance sensitivity while maintaining specificity. A research category of possible prodromal MSA is designed to capture patients in the earliest stages when symptoms and signs are present, but do not meet the threshold for clinically established or clinically probable MSA. Brain magnetic resonance imaging markers suggestive of MSA are required for the diagnosis of clinically established MSA. The number of research biomarkers that support all clinical diagnostic categories will likely grow.
conclusionsThis set of MDS MSA diagnostic criteria aims at improving the diagnostic accuracy, particularly in early disease stages. It requires validation in a prospective clinical and a clinicopathological study. © 2022 The Authors. Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.